TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31044463

Group type: EXPERIMENTAL
Intervention: Low-dose aripiprazole (3 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose aripiprazole (up to 12 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Responder group (pHVA levels)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Non-responder group (pHVA levels)
Number of subjects: 31
Study: 28801464

Group type: EXPERIMENTAL
Intervention: Strong protax message
Number of subjects: 5147

Group type: EXPERIMENTAL
Intervention: Two-sided message
Number of subjects: 5147

Group type: EXPERIMENTAL
Intervention: Refutation message
Number of subjects: 5147

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 5147
Study: 24961497

Group type: EXPERIMENTAL
Intervention: Children with more category knowledge
Number of subjects: 2

Group type: COMPARATOR
Intervention: Children with less category knowledge
Number of subjects: 2

Group type: COMPARATOR
Intervention: Adults
Number of subjects: 2
Study: 24096043

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at low (1 μg/kg/hr) and high (3 μg/kg/hr) doses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol (PROP) at low (100 μg/kg/m) and high (200 μg/kg/m) doses
Number of subjects: 60
Study: 21305525

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/m² (maximum 20 mg) once weekly for 12 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19246658

Group type: EXPERIMENTAL
Intervention: CRT(on)
Number of subjects: 7
Study: 17535144

Group type: EXPERIMENTAL
Intervention: Warm-up
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cool-down
Number of subjects: 52
Study: 15155194

Group type: EXPERIMENTAL
Intervention: Anidulafungin 50 mg once daily
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Anidulafungin 75 mg once daily
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Anidulafungin 100 mg once daily
Number of subjects: 123
Study: 11904267

Group type: EXPERIMENTAL
Intervention: Regional nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous analgesia
Number of subjects: 0
Study: 9988206

Group type: EXPERIMENTAL
Intervention: Grass pollen extract in a hydroglyceric solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7751994

Group type: EXPERIMENTAL
Intervention: 20 micrograms HB vaccine (Group A)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 10 micrograms HB vaccine (Group B)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 20 micrograms HB vaccine (Group C)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 171
Study: 2077437

Group type: EXPERIMENTAL
Intervention: desglycinamide-(arg8) vasopressin (DGAVP) 2 mg, nasal route
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7022423

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bumetanide vs Bendrofluazide
Number of subjects: 18
Study: 31498950

Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg administered as three loading doses every 4 weeks, then every 8 weeks until week 48
Number of subjects: 18
Study: 29283292

Group type: EXPERIMENTAL
Intervention: Morning resistance training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Afternoon resistance training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pre-training acute loading
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-training acute loading in morning group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-training acute loading in all groups
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resting cortisol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resting testosterone
Number of subjects: 25
Study: 25803657

Group type: EXPERIMENTAL
Intervention: Cervical-spine rotation active joint-position sense (AJPS) at end-range of motion (60°)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cervical-spine rotation active joint-position sense (AJPS) at mid-range of motion (30°)
Number of subjects: 53
Study: 25255447

Group type: EXPERIMENTAL
Intervention: LD-aminopterin (0.007, 0.014, 0.021 mg/kg once-weekly)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LD-aminopterin (0.007 mg/kg twice-weekly)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22696863

Group type: EXPERIMENTAL
Intervention: 0.1% timolol eye gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.5% timolol eye drop
Number of subjects: 25
Study: 20822191

Group type: EXPERIMENTAL
Intervention: Emotionally vulnerable (EV) gamblers
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Antisocial impulsive (AI) gamblers
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: AI and EV gamblers
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: All three subtypes (AI, EV, BC)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Pathways subtypes
Number of subjects: 229
Study: 17393018

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (25 microg 17beta‐estradiol/125 microg norethisterone acetate applied every 3-4 days)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Oral hormone therapy (estradiol 1 mg and NETA 0.5 mg given once daily)
Number of subjects: 344
Study: 15803450

Group type: EXPERIMENTAL
Intervention: Maximum likelihood methods to estimate the effect of intervention in the context of mixture distributions
Number of subjects: 0
Study: 11965609

Group type: EXPERIMENTAL
Intervention: (90)Y DOTATOC
Number of subjects: 256
Study: 9624598

Group type: EXPERIMENTAL
Intervention: hexarelin + placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: hexarelin + TRH
Number of subjects: 7

Group type: COMPARATOR
Intervention: TRH + placebo
Number of subjects: 7
Study: 7519693

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/o.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2497985

Group type: EXPERIMENTAL
Intervention: Minitran
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nitro-Dur II (ND II)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 65
Study: 30913304

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus ziv-aflibercept (4 mg/kg every 2 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: mFOLFOX6 plus placebo
Number of subjects: 64
Study: 28163068

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) treatment on one side of the face
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment on the other side of the face
Number of subjects: 20
Study: 26759214

Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg once daily)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 24734338

Group type: EXPERIMENTAL
Intervention: Implant-link semi cement application
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional burs or Piezosurgery device
Number of subjects: 25
Study: 20861750

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 2 g daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 18302285

Group type: EXPERIMENTAL
Intervention: Debio‐025 (1200 mg twice daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Debio‐025
Number of subjects: 0
Study: 17201845

Group type: EXPERIMENTAL
Intervention: Propofol at sedative doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14627865

Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 50 microg transdermal 17beta‐estradiol (tE2, n = 33)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 1 mg oral 17beta‐estradiol (oE2, n = 37)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 1 mg oral 17beta‐estradiol combined with 25 microg gestodene (oE2 + G, n = 33)
Number of subjects: 152
Study: 10725476

Group type: EXPERIMENTAL
Intervention: Intravaginal indomethacin (200 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intrarectal plus oral indomethacin (200 mg)
Number of subjects: 46
Study: 8870161

Group type: EXPERIMENTAL
Intervention: Bootstrap method that resamples clusters
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximum likelihood based on the normal mixed linear model
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Four-stage method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations
Number of subjects: 10

Group type: COMPARATOR
Intervention: All four methods
Number of subjects: 10
Study: 8504041

Group type: EXPERIMENTAL
Intervention: SPF 15+, broad‐spectrum, water‐resistant sunscreen cream
Number of subjects: 603

Group type: COMPARATOR
Intervention: Cream base without active ingredients (Control)
Number of subjects: 603
Study: 3551494

Group type: EXPERIMENTAL
Intervention: Guar diet (5% of daily carbohydrate intake)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Guar + fructose diet (1 g of fructose/kg body weight, max 30 g/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no guar supplementation)
Number of subjects: 22
Study: 31965073

Group type: EXPERIMENTAL
Intervention: Mobile health-supported lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 29430845

Group type: EXPERIMENTAL
Intervention: Peer counselling
Number of subjects: 367

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 367
Study: 27298740

Group type: EXPERIMENTAL
Intervention: Theta-tACS (6 Hz) for 20 minutes during implicit language learning
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 2
Study: 25807130

Group type: EXPERIMENTAL
Intervention: Liposomal capsaicin (LC) 0.025%
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 21986721

Group type: EXPERIMENTAL
Intervention: URMEL-ICE intervention
Number of subjects: 365
Study: 21680251

Group type: EXPERIMENTAL
Intervention: Stepped care intervention (n = 123)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Treatment as usual (n = 127)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Nondepressed patients (n = 250)
Number of subjects: 500
Study: 19892055

Group type: EXPERIMENTAL
Intervention: Active intervention (worksite health education, nutritional counseling, smoking cessation counseling, physical activity promotion, selected physician referral, and other health counseling)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 339

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 339
Study: 16537665

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20506

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 20506
Study: 12752017

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 11083131

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg day(‐1))
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9332632

Group type: EXPERIMENTAL
Intervention: Abbreviated NIH Stroke Scale based on facial palsy, motor arm, and dysarthria
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Proposed Out-of-hospital NIH Stroke Scale consisting of facial palsy, motor arm, and abnormal speech
Number of subjects: 299

Group type: COMPARATOR
Intervention: Non-stroke patients
Number of subjects: 299
Study: 8437068

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25%, 0.7 mL/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 3743795

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follicle aspiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follicle aspiration and CC use
Number of subjects: 0

Group type: COMPARATOR
Intervention: No CC treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follicle aspiration or general anesthesia
Number of subjects: 0
Study: 30025522

Group type: EXPERIMENTAL
Intervention: Magnesium (250 mg/day) plus Vitamin E (400 IU/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27660192

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (16 cycles of 7.5 mg/kg bevacizumab by intravenous infusion over 90 min on day 1 of each cycle)
Number of subjects: 1941

Group type: COMPARATOR
Intervention: Capecitabine alone (1250 mg/m2 twice daily for 14 days followed by a break for 7 days for 8 cycles)
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab
Number of subjects: 1941

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 1941
Study: 24768895

Group type: EXPERIMENTAL
Intervention: MSG broth (0.5 g/100 ml)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MSG+ broth (0.05 g/100 ml)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control preload (low-energy chicken flavor broth, 200 ml)
Number of subjects: 86
Study: 22475864

Group type: EXPERIMENTAL
Intervention: 3.75 μg hemagglutinin antigen
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 7.5 μg hemagglutinin antigen
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 408
Study: 20417423

Group type: EXPERIMENTAL
Intervention: Fentanyl, 1 microg/kg, and ketamine, 0.5 mg/kg (group FK)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl, 1 microg/kg, and normal saline solution (group F)
Number of subjects: 80
Study: 18600492

Group type: EXPERIMENTAL
Intervention: Zinc-monocysteine (ZMC) 25 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15810046

Group type: EXPERIMENTAL
Intervention: Preoperative duplex imaging (group 1; 166 legs)
Number of subjects: 293

Group type: COMPARATOR
Intervention: No preoperative duplex imaging (group 2; 177 legs)
Number of subjects: 293
Study: 14508828

Group type: EXPERIMENTAL
Intervention: Predictive nomogram incorporating clinical, laboratory, and TRUS data
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Prediction based on PSA alone
Number of subjects: 1237
Study: 12022177

Group type: EXPERIMENTAL
Intervention: Tea polyphenols (TP) 600 mg/d orally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 8685327

Group type: EXPERIMENTAL
Intervention: BIP gun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manan gun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biopsy gun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASAP gun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temno gun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BIP gun (breast parenchyma model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manan gun (breast parenchyma model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biopsy gun (breast parenchyma model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASAP gun (breast parenchyma model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temno gun (breast parenchyma model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monopty gun (breast parenchyma model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultra-Cut gun (breast parenchyma model)
Number of subjects: 0
Study: 1376694

Group type: EXPERIMENTAL
Intervention: Acetorphan (200 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3903709

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 78

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 78
Study: 30719817

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.1 mg kg-1 hr-1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 70
Study: 29420994

Group type: EXPERIMENTAL
Intervention: l-Theanine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: l-Theanine-Caffeine combination
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 9
Study: 26914113

Group type: EXPERIMENTAL
Intervention: SCUBE‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sCD40L
Number of subjects: 90
Study: 25331395

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration and bone graft therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Flap surgery
Number of subjects: 38
Study: 22316337

Group type: EXPERIMENTAL
Intervention: Education intervention (EI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Education and nutrition intervention (EIN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 20589924

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 400 mg of caffeine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18540714

Group type: EXPERIMENTAL
Intervention: Expectancy Challenge (EC) intervention
Number of subjects: 217

Group type: COMPARATOR
Intervention: CD-ROM alcohol education
Number of subjects: 217

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 217
Study: 16029638

Group type: EXPERIMENTAL
Intervention: Modified TME and anal sphincter preservation combined with brachytherapy by (125)I seed implantation (group B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Rectostomy and anal sphincter preservation (group A)
Number of subjects: 76
Study: 12635747

Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin (hMG)
Number of subjects: 99

Group type: COMPARATOR
Intervention: highly purified follicle stimulating hormone (pFSH)
Number of subjects: 99
Study: 10335496

Group type: EXPERIMENTAL
Intervention: remacemide hydrochloride
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 340
Study: 7579435

Group type: EXPERIMENTAL
Intervention: Streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Streptokinase 250,000 IU over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2010447

Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg/L in crystalloid potassium cardioplegia)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (same cardioplegia without diltiazem)
Number of subjects: 12
Study: 6838742

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neuroleptanaesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 29505552

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 1875

Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 1875

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 1875
Study: 29536389

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lanthanum carbonate
Number of subjects: 200
Study: 27060836

Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a (125 μg s.c.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (44 μg s.c. three times per week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a
Number of subjects: 30
Study: 24952693

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 813

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Addition of ST2 and galectin-3
Number of subjects: 813
Study: 22240389

Group type: EXPERIMENTAL
Intervention: Fast dissolving oral film containing 4 mg dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablet containing 8 mg dexamethasone
Number of subjects: 0
Study: 19962411

Group type: EXPERIMENTAL
Intervention: Passive head up tilt (HUT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mental arithmetic (MA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined MA+HUT
Number of subjects: 15

Group type: COMPARATOR
Intervention: HUT
Number of subjects: 15

Group type: COMPARATOR
Intervention: MA+HUT
Number of subjects: 15
Study: 17483542

Group type: COMPARATOR
Intervention: Ramipril 10 mg and placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg and Candesartan 16 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Candesartan 16 mg and placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination therapy (Ramipril 10 mg and Candesartan 16 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ramipril therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Candesartan therapy
Number of subjects: 34
Study: 16305585

Group type: EXPERIMENTAL
Intervention: BMS‐193884 (200 mg, oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS‐193884 (50 nmol min(‐1), intra-arterial)
Number of subjects: 0
Study: 12195542

Group type: EXPERIMENTAL
Intervention: Telephone interventions
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 216
Study: 9794714

Group type: COMPARATOR
Intervention: Antihypertensive treatment (placebo-controlled randomized trial)
Number of subjects: 631
Study: 7657739

Group type: EXPERIMENTAL
Intervention: Gonadotrophins (1.5 to 2.5 ampoules per day, decreasing by 0.5 ampoules/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Gonadotrophins
Number of subjects: 82
Study: 2706175

Group type: EXPERIMENTAL
Intervention: Orogastric tube followed by 30 ml of sodium citrate 0.3 mol litre‐1
Number of subjects: 183

Group type: COMPARATOR
Intervention: 30 ml of sodium citrate 0.3 mol litre‐1
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ranitidine 50 mg i.v. before operation, in addition to sodium citrate
Number of subjects: 183
Study: 811573

Group type: EXPERIMENTAL
Intervention: Sulfanilamide and sulfathiazole cones
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 94